Treatments for multiple sclerosis have long focused on slowing or stopping the acute disease process, which moves quickly and ...

With Pfizer’s revenue and share price slumping after the drugmaker skyrocketed to new heights during the pandemic, the ...

A decade into reformulating Pfizer’s oral renal cell carcinoma drug Inlyta (axitinib) into a treatment that can be injected ...

After third-party manufacturing issues led to a December rejection of Zealand Pharma’s pediatric congenital hyperinsulinism (CHI) candidate, the Danish pharma’s latest snub seems to come down to ti | ...

A trial of Biogen’s spinal muscular atrophy (SMA) therapy Spinraza (nusinersen) suggests that a higher dose provides benefits ...

Is your company bracing for Milton or working to provide aid in anticipation of the storm? | Pfizer—which opened a global hub ...

The Congressional Budget Office found that only one out of the seven policies it reviewed would create notable reductions in ...

While recent CDC guidance threatens to shrink the market for a new class of immunizations, GSK continues to build the case ...

Eversana is increasing its reach across the global pharmaceutical industry. | Eversana is increasing its reach across the ...

With an estimated 2 million people in the United States taking copycat vers | A compounding industry group has sued the FDA, ...

Bausch + Lomb has teamed up with American sportscaster Erin Andrews to promote its dry eye disease treatment, launching the ...

Merck & Co. hopes a new positive trial readout can return Keytruda to glory in head and neck cancer. | Merck & Co. hopes a ...